Rituximab Induction Dosing for Inflammatory Myositis
Primary Dosing Regimens
- The American College of Physicians recommends administering rituximab 1000 mg IV on day 0 and repeat 1000 mg IV on day 15 for adults with inflammatory myositis, with a favorable response of 83% in 200 pediatric and adult patients with refractory disease over 44 weeks 1, 2, 3
- The dosing regimen of 1000 mg IV on day 0, repeated on day 15, showed significant reduction in muscle enzyme levels and improvements in strength, disease activity, and quality of life scores at 27.1 months follow-up, with a strength of evidence rated as high 1, 3
- An alternative regimen of 375 mg/m² IV once weekly for 4 consecutive weeks demonstrated improvement in muscle strength, reduction of CK levels, and improved cutaneous and pulmonary disease after 12 weeks in open-label trials, with a moderate strength of evidence 1, 2, 4
Pre-Treatment Screening Requirements
- The American Academy of Rheumatology recommends obtaining immunoglobulin levels, hepatitis B and C antibody screening, and latent tuberculosis screening before initiating rituximab, with a high strength of evidence 1, 3, 4
- A complete blood count with differential is also recommended before treatment, with a moderate strength of evidence 4
Clinical Context and Patient Selection
- The European League Against Rheumatism recommends rituximab for patients with refractory inflammatory myositis despite corticosteroids and at least one conventional immunosuppressant, with a high strength of evidence 1, 2
- Rituximab is also indicated for patients with severe disease complications, including interstitial lung disease, severe cutaneous manifestations, or organ involvement, with a moderate strength of evidence 1, 2
Monitoring and Safety Considerations
- The American College of Rheumatology recommends monitoring for muscle strength improvement, which is progressive over 12 weeks, with a moderate strength of evidence 1
- Infusion reactions occur in up to 77% during first infusion, manageable with premedication, with a high strength of evidence 4
- Cytopenias require monitoring of CBC at 2-4 month intervals during treatment, with a moderate strength of evidence 4
- Progressive multifocal leukoencephalopathy and hepatitis B reactivation are critical safety warnings, with a high strength of evidence 1, 3, 4
Maintenance and Retreatment
- The British Society for Rheumatology recommends maintenance dosing of rituximab every 24 weeks based on clinical response, with a moderate strength of evidence 4, 5
Rituximab Therapy Monitoring and Screening
Pre-Treatment Screening and Baseline Tests
- The European League Against Rheumatism recommends measuring serum immunoglobulin levels (IgG, IgA, IgM) at baseline, as pre-existing hypogammaglobulinemia (IgG <6 g/L) predicts increased risk of developing severe hypogammaglobulinemia and serious infections after rituximab 6, 7
Critical Hepatitis B Management
- The American College of Rheumatology recommends prophylactic antiviral therapy over monitoring alone when initiating rituximab in patients who are hepatitis B core antibody positive, regardless of hepatitis B surface antigen status, to prevent hepatitis B reactivation 8
Rationale for Immunoglobulin Monitoring
- The Kidney Disease: Improving Global Outcomes guideline suggests that pre-existing hypogammaglobulinemia (IgG <3 g/L) predicts greater risk of secondary immunodeficiency with rituximab, and baseline IgG levels correlate with post-rituximab hypogammaglobulinemia 7
Pre‑Rituximab Screening, Prophylaxis, and Vaccination Guidelines
Infectious‑Disease Screening
- Comprehensive pre‑rituximab screening should include hepatitis B serologies (HBsAg and anti‑HBc), hepatitis C antibody testing, latent tuberculosis assessment, a complete blood count with differential, and baseline serum immunoglobulin levels (IgG, IgA, IgM). 9
- Rituximab is classified as a high‑risk immunosuppressive agent for hepatitis B reactivation. 10
Antiviral Prophylaxis for Hepatitis B
- Patients who are HBsAg‑positive or anti‑HBc‑positive (regardless of HBsAg status) should receive prophylactic antiviral therapy with entecavir or tenofovir before starting rituximab. 10
- Antiviral prophylaxis should be initiated 2–4 weeks prior to the first rituximab infusion. 10, 11
- Prophylaxis must be continued for at least 12 months after the final rituximab dose (and may be extended to 24 months) because reactivation can occur up to 1–2 years post‑therapy. 10, 11
- Do not rely solely on HBsAg for hepatitis B screening; anti‑HBc must also be checked because resolved infection (HBsAg‑negative/anti‑HBc‑positive) still carries reactivation risk. 10, 11
Baseline Laboratory Testing
- Obtain a CBC with differential and platelet count before the first rituximab dose to establish baseline values for monitoring cytopenias, a known toxicity of rituximab. 9
Vaccination Strategy
- All indicated vaccines should be administered before rituximab initiation whenever feasible. 12, 13
- Humoral responses to vaccines—especially influenza and pneumococcal—are markedly impaired for 1–6 months after rituximab, making early vaccination critical. 12, 13
- If a patient is already receiving rituximab, vaccines should be given at least 6 months after the last infusion and at least 4 weeks before the next scheduled dose. 12, 13
- Priority vaccines include:
- Pneumococcal vaccine (PCV followed by PPSV23)
- Annual influenza vaccine
- Hepatitis B vaccine (if non‑immune)
- Tetanus toxoid
- Haemophilus influenzae b vaccine
- Hepatitis A vaccine
- Neisseria meningitidis vaccine
- Rubella vaccine (for women of child‑bearing age)
All of the above are recommended before rituximab.* 12, 13
- Herpes zoster vaccination may be considered in patients with mild immunosuppression who have positive varicella‑zoster antibody titers. 12, 13
- Live vaccines should generally be withheld once rituximab therapy has begun. 14